In conclusion, the profiling of surface GSL-related epitopes together with specific protein molecules represented by markers of phenotypic plasticity (e.g., EpCAM) or by approved clinical targets (e.g., TROP2) (60, 61) is a promising strategy for the future expansion of therapeutic possibilities namely in clinically aggressive breast cancer subtypes such as TNBC. This evidence concerns the gene EPCAM and breast carcinoma.